

Receipt date: 05/29/2007

10525690 - GAU: 1626

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10525690
	Filing Date		2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.	
	Art Unit	1614	
	Examiner Name	not yet assigned	
	Attorney Docket Number	16526US01	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3297710	B1	1967-01-10	Silversmith	
	2	4089747	B1	1978-05-16	Bruschi	
	3	4423046	B1	1983-12-27	Carlson	
	4	4466976	B1	1984-08-21	Klose et al.	
	5	4585771	B1	1986-04-29	Klose et al.	
	6	4705855	B1	1987-11-10	Desideri et al.	
	7	4721670	B1	1988-01-26	Osada et al.	
	8	4902705	B1	1990-02-20	Hirota et al.	

/Fiona T. Powers/

11/16/2009

EFS Web 2.0

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FTP/

Receipt date: 05/29/2007

10525690 - GAU: 1626

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10525690	
	Filing Date		2006-10-24	
	First Named Inventor	Raed, Al-Qawasmeh et al.		
	Art Unit	1614		
	Examiner Name	not yet assigned		
	Attorney Docket Number	16526US01		

	9	4970226	B1	1990-11-13	Sun	
	10	5011472	B1	1991-04-30	Aebischer	
	11	5023252	B1	1991-06-11	Hsieh	
	12	5024935	B1	1991-06-18	McClune	
	13	5047318	B1	1991-09-10	Snyder	
	14	5496702	B1	1996-03-05	Bishop	
	15	5514550	B1	1996-05-07	Findlay	
	16	5656644	B1	1997-08-12	Adams	
	17	5686455	B1	1997-11-11	Adams	
	18	5693589	B1	1997-12-02	Goswami	
	19	5753687	B1	1998-05-19	Mjalli	

Receipt date: 05/29/2007

10525690 - GAU: 1626

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

	20	5916891	B1	1999-06-29	Adams	
	21	5945418	B1	1999-08-31	Bemis	
	22	6060216	B1	2000-05-09	Ichikawa	
	23	6117609	B1	2000-09-12	Maeda	
	24	6194441	B1	2001-02-27	Roberts	
	25	6268370	B1	2001-07-31	Adams	
	26	6288212	B1	2001-09-11	Hancock	
	27	6521655	B1	2003-02-18	Beers	
	28	3279918	B1	1966-10-18	Cassiers	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
-------------------	---------	--------------------	------------------------	------------------	---	--

Receipt date: 05/29/2007

10525690 - GAU: 1626

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

1	20040176601	A1	2004-09-09	Goulet	
---	-------------	----	------------	--------	--

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	CA1195325	CA	B1	1985-10-15	Klose Walter; Boettcher Imgard		<input type="checkbox"/>
	2	JP2002275458	JP	A1	2002-09-25	Fukuoka Prefecture		<input type="checkbox"/>
	3	WO 0078761	WO		2000-12-28	SEPRACOR, Inc.		<input checked="" type="checkbox"/>
	4	WO 03004023	WO	A1	2003-01-16	Schering Aktiengesellschaft		<input type="checkbox"/>
	5	WO 9827065	WO	A1	1998-06-25	Ontogen Corp.		<input checked="" type="checkbox"/>
	6	CA 2351694	CA	A1	1993-07-22	SmithKline Beecham Corp.		<input checked="" type="checkbox"/>
	7	WO 0224680	WO	A1	2002-03-28	SmithKline Beecham P.L.C.		<input checked="" type="checkbox"/>
	8	WO 0126467	WO	A1	2001-04-19	Ontogen Corp.		<input checked="" type="checkbox"/>

/Fiona T. Powers/

11/16/2009

EFS Web 2.0

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FTP/

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

	9	WO 0059541	WO	A1	2000-03-03	Sankyo Company	<input type="checkbox"/>
	10	WO 02083111	WO	A2	2002-10-24	Tanabe Seiyaku Co., Ltd	<input checked="" type="checkbox"/>
	11	DE 3141063	DE	A1	1985-10-15	Schering AG	<input type="checkbox"/>
	12	WO 9902155	WO	A1	1999-01-21	Ontogen Corp.	<input checked="" type="checkbox"/>
	13	WO 0246168	WO	A1	2002-06-13	AstraZeneca AB	<input checked="" type="checkbox"/>
	14	EP 165588	EP	A2	1985-12-27	Fuji Photo Film Co., Ltd	<input checked="" type="checkbox"/>
	15	EP 0812829	EP	A1	1997-12-17	Ontogen Corporation	<input checked="" type="checkbox"/>
	16	WO 0033836	WO	A1	2000-06-15	Ontogen Corporation	<input checked="" type="checkbox"/>
	17	WO 9618626	WO	A1	1996-06-20	F. Hoffmann-La Roche AG	<input checked="" type="checkbox"/>
	18	WO 9503297	WO	A1	1995-02-02	SmithKline Beecham Corp.	<input checked="" type="checkbox"/>
	19	WO 9314081	WO	A1	1993-07-22	SmithKline Beecham Corp.	<input checked="" type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

	20	WO 03087026	WO	A1	2003-10-23	F.Hoffmann-La Roche AG	<input checked="" type="checkbox"/>
	21	WO 09736587	WO	A1	1997-10-09	Merck & Co., Inc.	<input checked="" type="checkbox"/>
	22	WO 9827108	WO	A2	1998-06-25	Fujisawa Pharmaceutical Col, Ltd.	<input checked="" type="checkbox"/>
	23	WO 9901128	WO	A1	1999-01-14	Neurogen Corp.	<input checked="" type="checkbox"/>
	24	WO 9907701	WO	A1	1999-02-18	Sugen, Inc.	<input checked="" type="checkbox"/>
	25	WO 2004016086	WO	A2	2004-02-26	Lorus Therapeutics Inc.	<input checked="" type="checkbox"/>
	26	WO 2005047266	WO	A1	2005-05-26	Lorus Therapeutics Inc.	<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	JOHN LEWIS; Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids; Natural Product Reports; 1998; 15: 417-437; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>
	2	JOHN LEWIS; Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids; Natural Product Reports; 1998; 15: 371-395; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>

/Fiona T. Powers/

11/16/2009

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

3	JOHN LEWIS; Miscellaneous alkaloids: Amaryllidaceae, Scelletium, muscarine, imidazole, oxazole, peptide and other miscellaneous alkaloids; Natural Product Reports; 1999; 16: 389-416; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>
4	LoGRASSO et al; Kinetic Mechanism for p38 MAP Kinase; Biochemistry; 1997; 36: 10422-10427; American Chemical Society; Rahway, New Jersey, USA	<input checked="" type="checkbox"/>
5	LOW et al; Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32: S133-145; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
6	McLAY et al; The Discovery of RPR 200765A, a p38 MAP Kinase Inhibitor Displaying a Good Oral Anti-Arthritic Efficacy; Bioorganic & Medicinal Chemistry; 2001; 9: 537-554; Elsevier Science Ltd; Amsterdam, The Netherlands	<input checked="" type="checkbox"/>
7	HAMISH R. MICHIE; The value of animal models in the development of new drugs for the treatment of the sepsis syndrome; Journal for Antimicrobial Chemotherapy; 1998; 41: 47-49; British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
8	MICHAEL A. PFALLER, MD and WEN LIANG YU, MD; Antifungal Susceptibility Testing; Infectious Disease Clinics of North America; 2001; 15: 1227-145; Elsevier; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
9	PFALLER et al; Antifungal Susceptibility Testing: Technical Advances and Potential Clinical Applications; Clinical Infectious Diseases; 1997; 24: 776-84; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
10	SARSHAR et al.; Imidazole Libraries on Solid Support; Tetrahedron Letters; 1996; 37: 835-838; Elsevier Science Ltd.; London, UK.	<input checked="" type="checkbox"/>
11	SHIBATA et al.; Therapeutic efficacy of J-111, 225, a novel trans-3, 5-disubstituted pyrrolidinylthio-1 methylcarbapenem, against experimental murine systemic infections; Journal of Antimicrobial Chemotherapy; 2000; 45: 379-82; British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
12	SIMOR et al.; 1999 Canada Communicable Disease Report; 25: 105-108	<input checked="" type="checkbox"/>
13	STEVE STERNBERG; The Emerging Fungal Threat; Science; 1994; 266: 1632-1634; American Association for the Advancement of Science; Washington, DC, USA	<input checked="" type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

14	THALER et al.; Evaluation of Single-Drug and Combination Antifungal Therapy in an Experimental Model of Candidiasis in Rabbits with Prolonged Neutropenia; The Journal of Infectious Diseases; 1988; 158: 80-88; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
15	TOTSUKA et al.; Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo; Journal of Antimicrobial Chemotherapy; 1999; 44: 455-460; The British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
16	WALSH et al.; Effects of Preventive, Early, and Late Antifungal Chemotherapy with Fluconazole in Different Granulocytopenic Models of Experimental Disseminated Candidiasis; The Journal of Infectious Diseases; 1990; 161: 755-760; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
17	YANKE et al.; A CD-1 mouse model of infection with Staphylococcus aureus: Influence of gender on infection with MRSA and MSSA Isolates; Canada Journal of Microbiology; 2000; 46:920-926; NRC Research Press website	<input checked="" type="checkbox"/>
18	ZHANG et al; 2,4,5-Trisubstituted Imidazoles: Novel Nontoxic Modulators of P-glycoprotein Mediated Multidrug Resistance. Part 2; Bioorganic & Medicinal Chemistry Letters; 2000; 10: 2603-2605; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
19	GHANNOUM et al; Susceptibility Testing of Fungi: Current Status of Correlation of In Vitro Data with Clinical Outcome; Journal of Clinical Microbiology; 1996; 34: 489-495; American Society for Microbiology; Washington, DC, USA	<input type="checkbox"/>
20	ANTOLINI et al; Analogues of 4,5-bis(3,5-Dichlorophenyl)-2-Trifluoromethyl-1H-Imidazole as Potential Antibacterial Agents; Bioorganic and Medicinal Chemistry Letters; April 1999; 9(7):1023-1028; Elsevier Science Ltd; Philadelphia, PA, USA	<input type="checkbox"/>
21	ISIKDAG et al; QSAR of Inhibitory Activities by 2,4,5-Trisubstituted Imidazole Derivatives on Tubifex Worms; Acta Pharmaceutica Turcica; 1995; 37(1):19-24;	<input checked="" type="checkbox"/>
22	B. KRIEG and G. MANECKE; Synthese und Halbleitereigenschaften arylsubstituierter Imidazole; Naturforsch; 1967; 22b: 132-141	<input type="checkbox"/>
23	ABEL-MEGUID et al.; An Orally Bioavailable HIV-1 Protease Inhibitor Containing an Imidazole-Derived Peptide Bond Replacement: Crystallographic and Pharmacokinetic Analysis; Biochemistry; 1994: 33;11671 - 11677; American Chemical Society	<input checked="" type="checkbox"/>
24	ADAMS et al; Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity; Bioorganic and Medicinal Chemistry Letters; 2001; 11:2867-2870; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

25	ARROYO et al.; Therapy of Murine Aspergillosis with Amphotericin B in Combination with Rifampin or 5-Fluorocytosine; Antimicrobial Agents and Chemotherapy; 1977; pp. 21-25; American Society for Microbiology; Washington, DC, USA	<input checked="" type="checkbox"/>
26	XIU R. BU et al; A Novel Approach to Synthesis of Tricyanovinylthiophene for heterocyclic Imidazole Nonlinear Optical Chromophores; Tetrahedron Letters; 1996; 37: 7331-7334; Elsevier Science Ltd; London, UK	<input checked="" type="checkbox"/>
27	CHI, K.; Palladium Catalyst in DMSO For the Oxidation of Tolans to Benzils; Synthetic Communications; 1994; 24(15): 2119-2122; Marcel Dekker, Inc., now Taylor and Francis	<input checked="" type="checkbox"/>
28	CUENDA et al; Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38); The EMBO Journal; 1997; 16: 295-305; Oxford University Press; Oxford, UK	<input checked="" type="checkbox"/>
29	CUENDA et al; SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1; Federation of European Biochemical Societies Letters; 1995; 364: 229-33; Elsevier BV on behalf of Federation of European Biochemical Societies	<input checked="" type="checkbox"/>
30	DIEKEMA et al; Survey of Infections due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32: S114-132; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
31	EKWALL, BJORN; Screening of Toxic Compounds in Mammalian Cell Cultures; Annals New York Academy of Sciences; 1983; 407: 64-77; Blackwell Publishing	<input type="checkbox"/>
32	FISHCER et al; Dissociation Constants of the Conjugate Acids of Substituted Benzyl Phenyl Ketones and of Alkyl-substituted Benzophenones; Journal of American Chemical Society; 1961; 83: 4208-4210; American Chemical Society; Washington, DC, USA	<input checked="" type="checkbox"/>
33	GALES et al; Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32:S146-155; Infectious Disease Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
34	GOTO et al; Improved efficacy with nonsimultaneous administration of netilmicin and minocycline against methicillin - resistant Staphylococcus aureus in in vitro and in vivo models; International Journal of Antimicrobial Agents; 1999; 11:39-46; International Society of Chemotherapy; Elsevier Science B.V.; United Kingdom	<input checked="" type="checkbox"/>
35	GUIJARRO et al; The Reaction of Active Zinc with Organic Bromides; Journal of American Chemical Society; 1999; 121, 4155-4157; American Chemical Society; Washington, DC, USA	<input checked="" type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

36	HEERDING et al; 1,4 Disubstituted Imidazoles are Potential Antibacterial Agents Functioning as Inhibitors of Enoyl Acyl Carrier Protein Reductase (FabI); Biorganic and Medicinal Chemistry Letters; 2001, 11:2061-2065; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
37	HOBAN et al; Worldwide Prevalence of Antimicrobial Resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001: 32:S81-93; Infectious Disease Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
38	HUESCA et al; Adhesion and Virulence Properties of Epidemic Canadian Methicillin-Resistant Staphylococcus aureus Strain 1: Identification of Novel Adhesion Functions Associated with Plasmin-Sensitive Surface Protein; The Journal of Infectious Disease; 2002; Infectious Diseases Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
39	IWAHI et al; Virulence of Escherichia Coli in Ascending Urinary-Tract Infection in Mice; Journal of Medical Microbiology; 1982; 15:303-316; The Society for General Microbiology; HighWire Press	<input checked="" type="checkbox"/>
40	SARSHAR et al; 2,4,5-Trisubstituted Imidazoles: Novel Nontoxic Modulators of P-glycoprotein Mediated Multidrug Resistance. Part 1; Biorganic and Medicinal Chemistry Letters; 2000; 10:2599-2601; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
41	ARRESTO et al; A New Site Selective Synthesis of Benzoin Esters, Synthesis of Symmetrically and Unsymmetrically Substituted Benzils; Synthesis; 1988; 799-801	<input checked="" type="checkbox"/>
42	TANASEICHUK et al.; Uch. Zap., Mord. Univ. (1971), No. 81, 95-7 (From: Ref. Zh., Khim. 1972, Abstr. No. 12zh318 (English abstract)	<input type="checkbox"/>
43	BHADURI et al.; Potential Antifertility Agents: Syntheses of 2,4,5-Substituted Imidazoles; Indian Journal of Chemistry; 1966; 4(9): 419-20; NISCAIR; New Delhi, India	<input checked="" type="checkbox"/>
44	Database WPI; Section Ch. Week 199940, Derwent Publications Ltd., London, GB, Class B02, AN 1999-474062 (XP002268773) & JP 11199582 (english abstract) A (Sagami Chem Res Cent), July 27, 1999	<input checked="" type="checkbox"/>
45	LECHNER et al.; Differential Production of TNK by Kupffer cells after phagocytosis of E. coli and C. albicans; American Journal of Physiology; 1994; 10:1-8; American Physiological Society	<input checked="" type="checkbox"/>
46	KLOSE et al; The Suckling Mouse Model of Cholera; Trends in Microbiology; 2000; 8:189-91; Elsevier Science Ltd	<input checked="" type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10525690
	Filing Date	2006-10-24
	First Named Inventor	Raed, Al-Qawasmeh et al.
	Art Unit	1614
	Examiner Name	not yet assigned
	Attorney Docket Number	16526US01

47	LEE et al; A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis; Nature; 1994; 327: 739-745	<input checked="" type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button		
<b>EXAMINER SIGNATURE</b>		
Examiner Signature	/Fiona T. Powers/	Date Considered 11/16/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
<small><sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.</small>		